Clinical trials
Advanced clinical trials
Below are recruiting advanced clinical trials, each written for real people, not researchers. We’re tracking 3,986 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04939610RecruitingPhase 1/Phase 2
Studying a targeted radiation drug for advanced solid tumors
This trial tests how safe and effective a targeted radiation medicine (177Lu-FAP-2286) is for people with advanced solid cancers that have limited treatment options. It may help by delivering radiation directly to cancer-related targets and shrinking tumors.
Birmingham, AlabamaAges 18 years+ - NCT04649125Recruiting
Single-shot versus multi-day palliative radiation for metastatic cancer
This trial compares a single treatment session (one-fraction radiation) versus the usual multiple sessions (multi-fraction radiation) to help relieve symptoms from metastatic cancer. It may help your care team find the most effective and practical schedule for symptom control.
Saint Leonards, New South WalesAges Any age - NCT04348318Recruiting
Evaluating an advance care plan for ICU patients
This study looks at how well advance care planning documents are put into action for people who stay in the intensive care unit (ICU). If you participated, it may help the hospital improve how patients’ wishes are followed during serious illness.
AarauAges 18 years+ - NCT06870617Recruiting
Study on geriatric assessment for older adults with advanced cancer
This trial looks at using a practical geriatric assessment to help guide treatment for people aged 70 and older with advanced solid tumors. The goal is to see if this assessment improves care and outcomes.
Princeton, New JerseyAges 70 years+ - NCT06999798RecruitingPhase 1
A better ultrasound marker for lymph nodes in breast cancer
This trial tests a new ultrasound marker to help surgeons find and remove cancer-positive lymph nodes during breast cancer surgery. The marker makes the node easier to see on ultrasound so it can be taken out accurately.
Rochester, MinnesotaAges 18 years+ - NCT06793215RecruitingPhase 3
Divarasib plus pembrolizumab for KRAS G12C lung cancer
This trial compares a new targeted drug (divarasib) combined with an immunotherapy (pembrolizumab) versus standard chemotherapy plus immunotherapy for people with advanced lung cancer that has a specific KRAS G12C mutation. It aims to see if the new combination works better and is safe.
Anchorage, AlaskaAges 18 years+ - NCT07408531Recruiting
AI-enhanced lung cancer screening study
This trial uses artificial intelligence to better predict your lung cancer risk from your low-dose CT scan. You will watch a short video, answer a survey, and optionally give a blood sample to help improve future screening.
Chicago, IllinoisAges 50–80 - NCT07085234RecruitingPhase 2
New drug combo before radiation for advanced nasopharyngeal cancer
This trial tests a new immunotherapy drug (QL1706) combined with chemotherapy before standard radiation for advanced nasopharyngeal cancer. It aims to shrink tumors and improve outcomes.
Xiamen, FujianAges 18–65 - NCT07034352Recruiting
Health impact 360: improving heart health in community settings
This trial tests a community program to improve physical, social, and mental health to prevent heart disease. It may be a good fit if you can join group activities and speak English or Spanish.
Detroit, MichiganAges 18 years+ - NCT06946745Recruiting
Studying IBI363 combo for advanced colorectal cancer
This study tests a new combination therapy (IBI363 with other drugs) for advanced colorectal cancer that is pMMR/MSI-L/MSS. It aims to understand how the immune system around the tumor changes during treatment.
BeijingAges 18–75 - NCT06985368RecruitingPhase 1
Testing SIBP-A18 for advanced solid tumors
This trial tests a new drug, SIBP-A18, for people with advanced solid tumors that have not responded to standard treatments. It may be an option for those with certain cancers that have a protein called CLDN18.2.
Beijing, Beijing MunicipalityAges 18–75 - NCT06992687Enrolling by invitationPhase 1/Phase 2
Study of HB0052 for advanced solid tumors
This trial tests a new drug called HB0052 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective for various cancer types.
BeijingAges 18 years+ - NCT06808971RecruitingPhase 2
Perioperative drug combo for advanced stomach cancer
This study tests a combination of four drugs given before and after surgery for a type of stomach or throat-stomach cancer that can be removed. The drugs are adebrelimab (immunotherapy), nab-paclitaxel, oxaliplatin, and tegafur. The goal is to see if this combination works better than standard treatments.
BeijingAges 18–75 - NCT06804395Recruiting
Community cancer screening registry study
This study creates a registry to better understand and improve cancer screening for people at higher risk. By joining, you help researchers learn how to prevent and manage cancer in your community.
Totowa, New JerseyAges 18 years+ - NCT06825715Recruiting
Precision oncology support for lung and prostate cancer
This study tests a program to help veterans with lung or prostate cancer get personalized cancer treatments. The goal is to see if extra support for doctors and patients leads to better use of precision medicine.
New York, New YorkAges Any age - NCT06789679RecruitingPhase 2
Adding S-1 to standard chemo for advanced pancreatic cancer
This trial tests whether adding a third drug (S-1, a chemotherapy pill) to the standard two-drug IV chemo (albumin-bound paclitaxel and gemcitabine) can help people with advanced pancreatic cancer live longer. It's for those who haven't had treatment yet for their advanced cancer.
Beijing, Chaoyang DistrictAges 18 years+ - NCT06782334RecruitingPhase 1/Phase 2
AMT-116 for advanced solid tumors
This trial tests a new drug called AMT-116 in people with advanced solid tumors that have not responded to prior treatment. The goal is to see if it is safe and effective.
Fuzhou, FujianAges 18 years+ - NCT06667544RecruitingPhase 1/Phase 2
Study of RNK08954 for advanced cancers with KRAS G12D mutation
This trial tests a new oral drug called RNK08954 for people with advanced solid tumors that have a specific KRAS G12D genetic change. The drug targets this mutation to try to stop tumor growth. It is for patients who have already had other treatments and may not have many options left.
Nanning, GuangxiAges 18 years+ - NCT06706557Recruiting
Studying tumor DNA in HER2-low advanced breast cancer
This trial looks at tumor DNA in the blood of people with a certain type of advanced breast cancer called HER2-low. The goal is to learn more about this cancer and how it changes over time, which may help guide future treatments.
Milan, MIAges 18 years+ - NCT06622486RecruitingPhase 1/Phase 2
EGL-001 for advanced solid tumors after immunotherapy
This trial tests a new drug called EGL-001 for people with advanced solid tumors that have already been treated with immunotherapy. The goal is to see if the drug is safe and effective against cancer that has not responded to other treatments.
DijonAges 18 years+ - NCT06678880Recruiting
Sleep and light for mood during menopause
This study tests a program that combines better sleep habits with timed bright light exposure to help improve mood in women going through menopause. It may help reduce the sad or hopeless feelings that often come with this transition.
San Diego, CaliforniaAges 45–75 - NCT06630793Recruiting
Comparing types of radiation for anal cancer
This study compares standard radiation (IMRT) with a newer, more precise type (IMPT) both given alongside chemotherapy for anal cancer. It aims to see which is better at controlling cancer and reducing side effects.
Mumbai, MaharashtraAges 18–80 - NCT06647836Enrolling by invitation
Immunotherapy for advanced lung squamous cancer
This trial tests how well immunotherapy works as a first treatment for advanced lung squamous cell carcinoma, either alone or with chemotherapy. It aims to see if this approach can help patients who haven't had prior cancer treatment.
Wuhan, HubeiAges 18–80 - NCT06632093Recruiting
Combination therapy for advanced liver cancer after standard treatment fails
This trial tests a triple combination of liver-directed chemotherapy (HAIC) plus immunotherapy (PD-1 inhibitor) and targeted therapy (Lenvatinib) for people with advanced liver cancer that has spread into the portal vein and who have already tried and failed standard treatments.
Shenyang, LiaoningAges 18–75
Hear when a new Advanced trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced?
- Yes. Clin2 currently lists 3,986 recruiting advanced studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.